WO2017209076A1 - Sanitary absorbent article - Google Patents

Abstract

This sanitary absorbent article (1) is provided with: an absorbent body (4) which includes a highly absorbent polymer (41); and a second sheet (5) which is provided to the skin-facing surface side of the absorbent body (4). The second sheet (5) is provided with a water-soluble haemagglutination agent (8). A skin-side adhesive (11U) is provided between a surface sheet (2) and the second sheet (5), and the surface sheet (2) and the skin-facing surface of the second sheet (5) are partially fixed to each other. The position in which the haemagglutination agent (8) is provided and the position in which the skin-side adhesive (11U) is provided overlap in a planar view.

Description

Sanitary absorbent articles

The present invention relates to a sanitary absorbent article.

Conventionally, an absorbent article in which a second sheet is disposed between the top sheet and the absorber is known from the viewpoint of temporarily storing the body fluid when transferring the body fluid from the top sheet to the absorber. However, when a thick nonwoven fabric or the like is used as the second sheet, the wearer may feel stiff or the body fluid may stay and may feel stuffy. On the other hand, when a thin nonwoven fabric or the like is used as the second sheet, the body fluid cannot be sufficiently stocked temporarily.

As another technique, a technique for improving various performances of the absorbent article by applying an agent that acts on the blood itself to change the state of the blood to the absorbent article is known. Patent Document 1 and Patent Document 2 disclose a technique for filtering the remaining components by using red blood cells in menstrual blood as a mass. Patent Document 1 exemplifies an inorganic metal salt as an agent for aggregating red blood cells, and Patent Document 2 exemplifies a partially hydrated dicarboxylic anhydride copolymer or polycation as a blood gelling agent. Patent Document 3 discloses a personal care absorbent article comprising a porous nonwoven web treated with a fluid treatment agent suitable for modifying red blood cells, comprising triblock containing polypropylene oxide and polyethylene oxide as fluid treatment agents Examples are polymers or polycations.

The applicant previously proposed an absorbent article containing a blood coagulant (Patent Document 4).

Japanese Patent Publication No. 38-17449 JP-A-57-153648 Special table 2002-528232 gazette Japanese Patent Laying-Open No. 2005-287997

The present invention relates to an absorbent body containing a superabsorbent polymer, a top sheet and a back sheet sandwiching the absorbent body, and a second sheet composed of a nonwoven fabric disposed between the top sheet and the absorbent body. Is a sanitary absorbent article. The second sheet includes a water-soluble hemagglutinating agent, a skin-side adhesive is disposed between the top sheet and the second sheet, and the top sheet and the skin facing surface of the second sheet are partially It is fixed to. When the absorbent article is viewed in plan, the position where the hemagglutinating agent is disposed overlaps the position where the skin-side adhesive is disposed.

FIG. 1 is a plan view of a sanitary napkin which is a preferred embodiment of the sanitary absorbent article of the present invention. FIG. 2 is a plan view showing the second sheet of the sanitary napkin shown in FIG. 1 and the skin facing surface side (surface sheet side) of the absorbent body. 3 is a cross-sectional view schematically showing a cross section taken along line III-III in FIG. FIG. 4 is an enlarged cross-sectional view of the second sheet and the absorbent body included in the sanitary napkin shown in FIG. FIG. 5 is a perspective view of a top sheet provided in the sanitary napkin shown in FIG. 1. FIG. 6 is a perspective view of an absorbent body according to another embodiment of the sanitary absorbent article of the present invention. FIG. 7 is a schematic diagram showing a cross-section along the circumferential direction of the fiber stacking drum preferably used for manufacturing the absorbent body shown in FIG. FIG. 8 is a cross-sectional view of a sanitary napkin according to another embodiment of the sanitary absorbent article of the present invention including the absorbent body shown in FIG.

Detailed Description of the Invention

In the sanitary napkins and the like described in Patent Document 1 and Patent Document 2, red blood cell components can be aggregated. However, menstrual blood that is continuously discharged is absorbed in the latter period by the aggregate formed in the initial stage. It will be disturbed. In the absorbent article described in Patent Document 3, red blood cell clusters are trapped between the fibers of the nonwoven web, but it is difficult to continuously ensure the absorption of blood by the mechanism. Further, Patent Documents 1 to 3 do not describe anything about a configuration in which a second sheet made of nonwoven fabric is disposed between the top sheet and the absorbent body.

Similarly, Patent Document 4 does not describe anything regarding a configuration in which a non-woven second sheet is disposed between the top sheet and the absorbent body. Therefore, Patent Document 4 does not naturally describe or suggest the positional relationship of the second sheet containing the hemagglutinating agent.

The present invention relates to a sanitary absorbent article that can eliminate the above-mentioned drawbacks of the prior art.

Hereinafter, the sanitary absorbent article of the present invention (hereinafter also referred to as an absorbent article) is based on a sanitary napkin 1 (hereinafter also referred to as “napkin 1”), which is a preferred embodiment thereof, with reference to the drawings. explain. The napkin 1 is constituted by an absorbent body 4 containing a superabsorbent polymer 41, a top sheet 2 and a back sheet 3 sandwiching the absorbent body 4, and a nonwoven fabric disposed between the top sheet 2 and the absorbent body 4. The second sheet 5 is provided. FIG. 1 shows a plan view of a napkin 1 which is a preferred embodiment of the sanitary absorbent article of the present invention, and FIG. 2 shows the skin facing of the absorbent body 4 and the second sheet 5 shown in FIG. The top view which shows the surface side (surface sheet side) is shown. FIG. 3 shows a cross-sectional view of the napkin 1. In addition, the sanitary absorbent article of the present invention is preferably used during female menstruation, and is preferable for menstrual blood absorption.

In the present embodiment, the absorbent body 4 of the napkin 1 is formed of an absorbent sheet as shown in FIG. 3. Specifically, the absorbent sheet has a structure in which a plurality of absorbent sheets overlap in the thickness direction. . In the napkin 1 of this embodiment, the absorber 4 formed from the absorbent sheet contains a superabsorbent polymer 41 and constituent fibers (see FIG. 4). In this embodiment, the napkin 1 is interposed between the liquid-permeable surface sheet 2 that forms the skin-facing surface, the back sheet 3 that forms the non-skin-facing surface, and both the sheets 2 and 3. It has the absorptive main body 10 which comprises the absorber 4 which becomes.

As shown in FIG. 1, the absorbent main body 10 of the napkin 1 is a wearer than the excretion part facing part B, which is disposed opposite to the excretion part (vagina mouth or the like) of the wearer when worn, and the wearer facing part B. The front part A is arranged closer to the stomach side (front side) and the rear part C is arranged closer to the wearer's back side (rear side) than the excretory part facing part B. The napkin 1 and the absorbent main body 10 have a longitudinal direction X corresponding to the wearer's front-rear direction and a lateral direction Y orthogonal to the longitudinal direction X. That is, the absorbent main body 10 is divided in the order of the front part A, the excretory part opposing part B, and the rear part C in the vertical direction X.

Moreover, in this specification, a skin opposing surface is a surface in the napkin 1 or its component (for example, surface sheet 2) orient | assigned to a wearer's skin side at the time of wear of the napkin 1, and a non-skin opposing surface is a napkin. 1 or a component thereof, which is a surface directed to the side opposite to the skin side (clothing side) when the napkin 1 is worn. Further, the longitudinal direction X coincides with the longitudinal direction of the napkin 1 and the absorbent main body 10, and the lateral direction Y coincides with the width direction (direction orthogonal to the longitudinal direction) of the napkin 1 and the absorbent main body 10.

In this embodiment, as shown in FIGS. 1 and 3, the napkin 1 is further laterally extended from both side portions along the longitudinal direction X of the excretory part-facing portion B of the absorbent main body 10 in addition to the absorbent main body 10. It has a pair of wing parts 10W and 10W extending outward of Y.

In the sanitary absorbent article of the present invention, when the excretory part facing part B has the wing part 10W like the napkin 1 of the present embodiment, the longitudinal direction of the absorbent article (the longitudinal direction of the absorbent article) , Means a region having a wing portion 10W (a region sandwiched between a root along the longitudinal direction X of one wing portion 10W and a root along the longitudinal direction X of the other wing portion 10W). . The excretion part opposing part B in the absorbent article which does not have a wing part is produced when the absorbent article is folded into a three-fold individual packaging form. With respect to two folding curves (not shown) crossing in the Y direction in the middle, it means a region surrounded by the first folding curve and the second folding curve counted from the front end in the longitudinal direction X of the absorbent article. To do.

In the napkin 1 of the present embodiment, the top sheet 2 covers the entire area of the skin facing surface of the absorbent body 4 as shown in FIG. 1, and the outer side in the lateral direction Y from both side edges along the longitudinal direction X of the absorbent body 4. It extends to the direction. On the other hand, the back sheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4 and further extends outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorbent body 4 to be described later. In addition, a side flap portion 10S is formed. The top sheet 2 and the back sheet 3 are joined to each other by known joining means such as an adhesive, heat seal, ultrasonic seal, and the like, at portions extending from both end edges in the longitudinal direction X of the absorber 4. In addition, between each of the top sheet 2 and the back sheet 3 and the absorbent body 4 may be joined by an adhesive.

In the napkin 1, as shown in FIGS. 1 and 3, the side sheets 7 are disposed on both sides along the longitudinal direction X of the skin facing surface of the absorbent main body 10 (skin facing surface of the top sheet 2). Preferably, the side sheet 7 is arranged over the entire length in the longitudinal direction X of the absorbent main body 10 so as to overlap the left and right side portions along the longitudinal direction X of the absorbent body 4 in plan view.

In the napkin 1, as shown in FIG. 1, the pair of side sheets 7 and 7 each have a linear first joining line 61 located in the excretory part facing part B and the longitudinal direction X of the first joining line 61. Are joined to the topsheet 2 by linear second joining lines 62 located in the front and rear (front part A and rear part C). In the napkin 1, the first joining lines 61 have a curved shape that protrudes outward in the lateral direction Y in plan view, and the second joining lines 62 extend so as to alternately intersect in the longitudinal direction in plan view. It is linear (zigzag linear). Thus, when the side sheet 7 is joined to the surface sheet 2 by the first joining line 61 and the second joining line 62 and fixed to the skin facing surface of the absorbent main body 10, as shown in FIG. A space P defined by the side sheet 7 and the top sheet 2 is formed inward in the lateral direction Y with respect to the first joint line 61 and the second joint line 62. Since the space P is opened toward the center in the lateral direction Y of the absorbent main body 10, body fluid such as menstrual blood flowing outward from the center in the lateral Y is accommodated in the space P. As a result, leakage of body fluid can be effectively prevented. It should be noted that a pair of leak-proof cuffs along the vertical direction X may be arranged by disposing an elastic member extending in the vertical direction X at the free ends of the pair of side sheets 7, 7. The leak-proof cuff has an upright property and can prevent the side leakage of menstrual blood disposed on the skin facing surface.

In the napkin 1, as shown in FIG. 1, the side flap part 10S protrudes greatly outward in the lateral direction Y at the excretory part facing part B, and thereby the left and right along the longitudinal direction X of the absorbent main body 10 A pair of wing portions 10W and 10W are extended on both sides.

The wing part 10W is used by being folded back to the non-skin facing surface side of the crotch part of clothes such as shorts. In the napkin 1, the wing portion 10 </ b> W has a substantially trapezoidal shape in which a lower base (a side longer than the upper base) is located on a side portion along the longitudinal direction X of the absorbent main body 10 in a plan view, as shown in FIG. 1. It has a shape. A wing portion adhesive portion (not shown) for fixing the wing portion 10W (napkin 1) to clothes (not shown) such as shorts is formed on the non-skin facing surface of the wing portion 10W. The wing portion 10W folded back to the non-skin facing surface (outer surface) side of the crotch portion of the clothes can be adhesively fixed to the crotch portion by the adhesive portion during use. Moreover, the main body adhesion part (not shown) for fixing the absorptive main body 10 to clothes, such as shorts, is also formed in the non-skin opposing surface of the absorptive main body 10.

As shown in FIGS. 1 and 3, the napkin 1 has a surface sheet 2, a second sheet 5, and an absorber 4 on the back sheet 3 side on the skin facing surface (skin facing surface of the top sheet 2) of the absorbent main body 10. A linear squeezing groove 9 that is integrally recessed is provided. Accordingly, the compressed groove 9 is a groove in which the density of each fiber as a constituent member is higher than the density of the peripheral portion of the groove with respect to the top sheet 2, the second sheet 5, and the absorber 4. “Linear” in the linear compressed groove 9 means that the shape of the groove (concave portion) is not limited to a straight line in a plan view but includes a curved line. Each line may be a continuous line or a discontinuous line such as a broken line. For example, the squeezing groove 9 may be composed of a row formed by a number of discontinuous point embosses.

In the napkin 1, as shown in FIG. 1, the pressing groove 9 includes a first lateral pressing groove 91 extending in the lateral direction Y at each of the front part A and the rear part C, and both sides of the excretory part facing part B. And a vertical compression groove 92 extending in the vertical direction X. In the napkin 1, the 1st horizontal pressing groove 91 of the front part A and the back part C is extended in the horizontal direction Y, forming the convex curvilinear shape toward the vertical direction X outward. Moreover, each vertical pressing groove 92 is extended in the vertical direction X, forming the convex curvilinear shape toward the inner side of the horizontal direction Y in the side part along the vertical direction X in the excretion part opposing part B. As shown in FIG. In the napkin 1, the first lateral pressing groove 91 in the front part A, one vertical pressing groove 92, the first horizontal pressing groove 91 in the rear part C, and the other vertical pressing groove 92 are connected to form a ring-shaped circumferential groove. Forming. Moreover, in the napkin 1, the pressing groove 9 has the 2nd horizontal pressing grooves 93 and 93 extended in the horizontal direction Y to the inner side of the vertical direction X rather than the 1st horizontal pressing groove 91 of the front part A and the back part C, respectively. Have. In the napkin 1, the 2nd horizontal pressing grooves 93 and 93 of the front part A and the rear part C are the curved shape convex toward the vertical direction X outward. In addition, as shown in FIG. 1, although the 2nd horizontal pressing grooves 93 and 93 of the napkin 1 are not connected with a pair of vertical pressing grooves 92 and 92, they may be connected. The compressed groove 9 formed in this way can effectively prevent liquid leakage from the periphery of the napkin 1 by suppressing diffusion of body fluid flowing in the plane direction on the top sheet 2.

In the napkin 1, as shown in FIG. 3, a second sheet 5 made of a nonwoven fabric is disposed between the top sheet 2 and the absorbent body 4. In the napkin 1, the second sheet 5 has a width (length in the horizontal direction Y) shorter than a width (length in the horizontal direction Y) of the absorber 4 as shown in FIGS. . In the napkin 1, the length of the second sheet 5 in the longitudinal direction X is longer than the length of the absorbent body 4 in the longitudinal direction X, and is arranged over the entire length of the napkin 1 in the longitudinal direction X. Thus, the second sheet 5 covers most of the skin facing surface of the absorbent body 4. The second sheet 5 is a sheet called a sublayer sheet in the technical field, which is a separate body from the top sheet 2 and the absorber 4. The second sheet 5 is a sheet that plays a role of improving the liquid permeability from the top sheet 2 to the absorber 4 or reducing the return of the liquid absorbed by the absorber 4 to the top sheet 2. . In the napkin 1, the second sheet 5 includes a water-soluble hemagglutinating agent 8. FIG. 4 shows an enlarged cross-sectional view of the absorbent body 4 and the second sheet 5 in the cross-sectional view shown in FIG.

The hemagglutinating agent 8 provided in the napkin 1 acts to agglutinate erythrocytes in the blood and separate the aggregates and plasma components from which the erythrocytes have aggregated. A preferred hemagglutinating agent has a property that, when 1000 ppm is added to simulated blood, at least two erythrocytes aggregate to form an aggregate while maintaining the fluidity of blood. Here, “the state in which the fluidity of blood is maintained” means that 10 g of pseudo blood to which a measurement sample agent is added is 10 g of a screw tube (manufactured by Maruem, product number “screw tube No. 4”, 14.5 mm in inner diameter of the mouth) , Body diameter 27 mm, total length 55 mm), and when the screw tube bottle containing the simulated blood is inverted 180 degrees, 60% or more of the simulated blood flows down within 20 seconds. Simulated blood means that the viscosity measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) is 8 mPa · s. The blood cell / plasma ratio of defibrinated horse blood (manufactured by Nippon Biotest Laboratories, Inc.) was prepared. Further, whether or not “two or more red blood cells aggregate to form an aggregate” is determined as follows. That is, the simulated blood to which 1000 ppm of the measurement sample agent was added was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring apparatus (manufactured by HORIBA, model number: LA-950V2, measurement condition: flow type cell). The average median diameter of the volume particle diameter measured at a temperature of 25 ° C. by a laser diffraction scattering method using a measurement, a circulation speed of 1 and no ultrasonic wave corresponds to the size of an aggregate in which two or more red blood cells are aggregated. When it is 10 μm or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.

As the water-soluble hemagglutinating agent 8 used in the sanitary absorbent article of the present invention, a cationic polymer is suitable. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride. The hemagglutinating agent 8 can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer. In the present invention, the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The “quaternary ammonium moiety” described below is also used in the same meaning and is a moiety that is positively charged in water. Further, in the present invention, the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things. In the present invention, the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers. When the hemagglutinating agent 8 includes a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer, the hemagglutinating agent 8 is , Quaternary ammonium salt homopolymer, quaternary ammonium salt copolymer and quaternary ammonium salt polycondensate may be included, or any combination of two or more may be included. You may go out. Moreover, a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types. Similarly, the quaternary ammonium salt copolymer can be used alone or in combination of two or more. Furthermore, similarly, a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types. In the present specification, the “hemagglutinating agent” refers to the aggregation of erythrocytes by a single compound capable of aggregating blood erythrocytes, or a plurality of combinations of the single compounds, or a combination of a plurality of compounds. It is an agent that develops. That is, the hemagglutinating agent is an agent limited to those having a hemagglutinating action. Therefore, when the hemagglutinating agent contains the third component, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent. Here, the term “single compound” is a concept including compounds having the same composition formula but having different molecular weights due to different numbers of repeating units.

Among the various cationic polymers described above, in particular, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate is advantageous from the viewpoint of adsorptivity to erythrocytes. preferable. In the following description, for convenience, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer and the quaternary ammonium salt polycondensate are collectively referred to as “quaternary ammonium salt polymer”.

The quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety. On the other hand, the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety. It is obtained by copolymerizing one or more polymerizable monomers having one or more polymerizable monomers having no quaternary ammonium moiety. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing two or more condensates having two or more monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.

The quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety. A quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent. Alternatively, the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce | generate by the quaternary ammonium formation by the nucleophilic reaction containing a condensation reaction. Examples of the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate. Of these alkylating agents, the use of dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. . In particular, it is preferable to use a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized. Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.

As a result of the inventor's examination, it has been found that it is particularly effective to use a cationic polymer in order to generate an aggregate of red blood cells during menstrual blood. The reason for this is as follows. Red blood cells have a red blood cell membrane on their surface. The erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer. The lipid film exposed on the surface of erythrocytes contains a protein called glycophorin. Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end. As a result, erythrocytes can be treated as colloidal particles having an anionic charge. In general, an aggregating agent is used for aggregating the colloidal particles. Considering that erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes. Further, if the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes. Further, when the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups.

From the viewpoint of effectively generating red blood cell aggregates, the cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more. When the molecular weight of the cationic polymer is not less than these values, the entanglement of the cationic polymers between the erythrocytes and the crosslinking of the cationic polymer between the erythrocytes are sufficiently caused. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less. When the molecular weight of the cationic polymer is not more than these values, the cationic polymer dissolves well into menstrual blood. The molecular weight of the cationic polymer is preferably 2000 or more and 10 million or less, more preferably 2000 or more and 5 million or less, still more preferably 2000 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferably 30,000 to 3,000,000. The molecular weight referred to in the present invention is a weight average molecular weight. Moreover, you may combine 2 or more types of cationic polymers of different molecular weight within the above-mentioned molecular weight range. The molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions. The molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows. As the column, a column in which a guard column α and an analytical column α-M manufactured by Tosoh Corporation are connected in series is used at a column temperature of 40 ° C. The detector uses RI (refractive index). As a measurement sample, 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 μL. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, elution with 50 mmol / L lithium bromide and 1% by mass acetic acid dissolved in ethanol: water = 3: 7 (volume ratio) Use liquid. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, a polyethylene glycol (PEG) having a molecular weight of 106, a PEG having a molecular weight of 400, a PEG having a molecular weight of 1470, and a PEG having a molecular weight of 6450 with respect to 20 mL of the eluent. Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 μL.

In the case of using a quaternary ammonium salt polymer as the cationic polymer, it is preferable that the quaternary ammonium salt polymer has a flow potential of 1500 μeq / L or more from the viewpoint of more effectively generating red blood cell aggregates. , More preferably 2000 μeq / L or more, still more preferably 3000 μeq / L or more, still more preferably 4000 μeq / L or more. When the flow potential of the quaternary ammonium salt polymer is not less than these values, the electric double layer of erythrocytes can be sufficiently neutralized. The upper limit of the streaming potential is preferably 13000 μeq / L or less, more preferably 8000 μeq / L or less, and even more preferably 6000 μeq / L or less. When the flow potential of the quaternary ammonium salt polymer is below these values, the electrical repulsion between the quaternary ammonium salt polymers adsorbed on the erythrocytes can be effectively prevented. The streaming potential of the quaternary ammonium salt polymer is preferably 1500 μeq / L or more and 13000 μeq / L, more preferably 2000 μeq / L or more and 13000 μeq / L or less, and 3000 μeq / L or more and 8000 μeq / L or less. Is more preferably 4000 μeq / L or more and 6000 μeq / L or less. The flow potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituting cationic monomer itself, and the copolymerization molar ratio of the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. Can be controlled. The streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. Specific measurement conditions are as follows. First, hot melt bonding each member to a commercially available napkin is invalidated using a dryer or the like, and decomposed into members such as a top sheet, an absorber, and a back sheet. For each decomposed member, a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent is performed to separate the treating agent used in each member to obtain a solution containing a single composition. The obtained solution was dried and solidified, and 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel) Permeation chromatography) and fluorescent X-rays are combined to identify the structure of the treatment agent. With respect to a measurement sample in which 0.001 g of a treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 10 g of physiological saline, a 0.001N sodium polyethylene sulfonate aqueous solution (if the measurement sample has a negative charge) , 0.001N polydiallyldimethylammonium chloride aqueous solution) is titrated, and the titer XmL required until the potential difference between the electrodes disappears is measured. Thereafter, the streaming potential of the quaternary ammonium salt polymer is calculated by Equation 1.
Streaming potential = (X + 0.190 *) × 1000 Equation 1
(* Titration required for the physiological saline solution)

In order for the cationic polymer to be successfully adsorbed on the surface of red blood cells, it is advantageous that the cationic polymer easily interacts with sialic acid present on the surface of red blood cells. From this point of view, the present inventors proceeded with studies, and as a result, inorganic value / organic value (hereinafter referred to as “IOB (Inorganic Organic Balance) value”), which is the ratio between the inorganic value and the organic value of the substance. It was found that the degree of interaction between the sialic acid conjugate and the cationic polymer can be evaluated on the basis of. Specifically, it has been found advantageous to use a cationic polymer having an IOB value that is the same as or close to that of the sialic acid conjugate. The sialic acid conjugate is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as galactolipid.

Generally, the properties of a substance are largely controlled by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Wals force due to molecular mass and electric affinity due to the polarity of the molecule. If the Van Der Waals force, which has a great influence on changes in the properties of substances, and the electrical affinity can be grasped individually, the properties of unknown substances or their mixtures can be predicted from the combination. be able to. This idea is a theory well known as “organic conceptual diagram”. Conceptual diagram of organic materials is, for example, “Organic analysis” written by Kei Fujita (Kanya Shoten, Showa 5), “Organic qualitative analysis: Systematic. Pure products” by Kyoda Fujita (Kyoritsu Shuppan, 1953), Jun Fujita “Revised Chemistry Experiments—Organic Chemistry” by Kawasaki Shobo (1971), “Systematic Organic Qualitative Analysis (mixture)” by Kaoru Fujita and Masami Akatsuka (Kasama Shobo, 1974), and Yoshio Koda It is described in detail in Shiro Sato and Yoshio Honma's “New Basic Concept of Organic Conception and Application” (Sankyo Publishing, 2008). In organic conceptual diagram, regarding the physicochemical properties of substances, the degree of physical properties due to Van Der Waals force is called `` organic '', and the degree of physical properties mainly due to electrical affinity is called `` inorganic ''. The physical properties of substances are considered as a combination of “organic” and “inorganic”. Then, one carbon (C) is defined as organic 20, and the inorganic and organic values of various polar groups are defined as shown in Table 1 below. The sum of the values is obtained, and the ratio between the two is defined as the IOB value. In the present invention, the IOB value of the sialic acid conjugate described above is determined based on these organic and inorganic values, and the IOB value of the cationic polymer is determined based on the value.

Specifically, when the cationic polymer is a homopolymer, the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated. For example, in the case of polydiallyldimethylammonium chloride, which is a cationic polymer, an organic value of −C− × 8 = 160, an inorganic value of Ammo and NH4 salt × 1 = 400, Ring (non-aromatic single ring) × Since it has an inorganic value of 1 = 10, an organic value of −Cl × 1 = 40, and an inorganic value of 10, the total of inorganic values is 400 + 10 + 10 = 420, and the total of organic values is 160 + 40 = 200. Therefore, the IOB value is 420/200 = 2.10.

On the other hand, when the cationic polymer is a copolymer, the IOB value is calculated according to the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from monomer A and monomer B, the organic value of monomer A is ORA, the inorganic value is INA, the organic value of monomer B is ORB, and the inorganic value is INB. Yes, when the molar ratio of monomer A / monomer B is MA / MB, the IOB value of the copolymer is calculated from the following equation.

The IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, 2.2 It is still more preferable that it is above. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. More preferably, it is 2.2 or more and 3.0 or less. The IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate. The sialic acid conjugate is a glycolipid in which a sugar chain in a glycolipid and sialic acid are bound, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than sialic acid alone.

Where the IOB value of the cationic polymer is as described above, the organic value itself is preferably 40 or more, more preferably 100 or more, and even more preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, still more preferably 240 or less, and even more preferably 190 or less. For example, the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, still more preferably 100 or more and 240 or less, and still more preferably 130 or more and 190 or less. By setting the organic value of the cationic polymer within this range, the cationic polymer is more successfully adsorbed to erythrocytes.

On the other hand, the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, still more preferably 100 or more, still more preferably 120 or more, and 250 or more. It is particularly preferred that Further, it is preferably 790 or less, more preferably 750 or less, still more preferably 700 or less, still more preferably 680 or less, and particularly preferably 490 or less. For example, the inorganic value is preferably from 70 to 790, more preferably from 90 to 750, even more preferably from 90 to 680, still more preferably from 120 to 680, It is especially preferable that it is 250 or more and 490 or less. By setting the inorganic value of the cationic polymer within this range, the cationic polymer can be more effectively adsorbed to erythrocytes.

From the viewpoint of further successfully adsorbing the cationic polymer to erythrocytes, it is preferable that x and y satisfy the following formula A when the organic value of the cationic polymer is x and the inorganic value is y.
y = ax (A)
In the formula, a is preferably 0.66 or more, more preferably 0.93 or more, and even more preferably 1.96 or more. Further, a is preferably 4.56 or less, more preferably 4.19 or less, and even more preferably 3.5 or less. For example, a is preferably a number from 0.66 to 4.56, more preferably from 0.93 to 4.19, and a number from 1.96 to 3.5. Is more preferable. In particular, when the organic value and the inorganic value of the cationic polymer satisfy the above formula A, provided that the organic value and the inorganic value of the cationic polymer are within the above-mentioned ranges, the cation The functional polymer is likely to interact with the sialic acid conjugate, and the cationic polymer is more easily adsorbed to erythrocytes.

From the viewpoint of effectively producing red blood cell aggregates, the cationic polymer is preferably water-soluble. In the present invention, “water-soluble” means that 0.05 g of a 1 mm or less powdery or 0.5 mm or less film-like cationic polymer is added to a 100 mL glass beaker (5 mmΦ) and mixed with 50 mL ion-exchanged water at 25 ° C. In this case, a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd. In the present invention, as a more preferable solubility, the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.

The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium moiety is preferably present in the side chain. In this case, when the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs. However, in the present invention, it is not hindered that the main chain and the side chain of the cationic polymer are bonded at two points or more. In the present invention, “bonded at one point” means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain. . “Connected at two or more points” means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain. Say.

When the cationic polymer has a structure having a main chain and a plurality of side chains bonded thereto, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto. In this case, the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less. The carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is in the above range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.

When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety. . In the case of polymerizing a vinyl monomer having a tertiary amine moiety, a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization. Becomes a polymer, becomes a tertiary amine neutralized salt obtained by neutralizing a tertiary amine site with an acid before and / or after polymerization, or becomes a tertiary amine having a cation in an aqueous solution after polymerization. . Examples of the alkylating agent and the acid are as described above.

In particular, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.

Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine. In addition, poly (2-methacryloxyethyldimethylamine quaternary salt), poly (2-methacryloxyethyltrimethylammonium salt) in which the side chain having a quaternary ammonium moiety is bonded to the main chain at one point. ), Poly (2-methacryloxyethyldimethylethylammonium methylsulfate), poly (2-acryloxyethyldimethylamine quaternary salt), poly (2-acryloxyethyltrimethylamine quaternary salt), poly (2-acryloxy) Ethyldimethylethylammonium ethyl sulfate), poly (3-dimethylaminopropylacrylamide quaternary salt), dimethylaminoethyl polymethacrylate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylaminopropylacrylamide, polyamidine, etc. And the like. On the other hand, examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.

When the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer. A copolymer obtained by the above copolymerization can be used. Alternatively, as the quaternary ammonium salt copolymer, one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety The copolymer obtained by copolymerizing using 1 or more types of bodies can be used. Furthermore, other polymerizable monomers such as —SO ₂ — may be used in addition to or instead of the vinyl polymerizable monomer. As described above, the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.

In particular, the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.

Also, as the polymerizable monomer having no quaternary ammonium moiety, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, in particular, by using a cationic polymerizable monomer or a nonionic polymerizable monomer, charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated. Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropane sulfonic acid, methacrylic acid, acrylic acid, styrene sulfonic acid, and salts of these compounds. On the other hand, examples of nonionic polymerizable monomers include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl Examples include acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate. One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do. Also, two or more cationic polymerizable monomers can be used in combination, two or more anionic polymerizable monomers can be used in combination, or two or more nonionic polymerizable monomers can be used in combination. Can also be used. A quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly preferably 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).

A polymerizable monomer having a functional group capable of hydrogen bonding can also be used as the polymerizable monomer having no quaternary ammonium moiety. When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using a quaternary ammonium salt copolymer obtained therefrom, a hard aggregate is likely to be formed. Absorption performance is less likely to be disturbed. Examples of the functional group capable of hydrogen bonding include —OH, —NH ₂ , —CHO, —COOH, —HF, —SH and the like. Examples of polymerizable monomers having functional groups capable of hydrogen bonding include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl An acrylate etc. are mentioned. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like, in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized. These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced. Examples of functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups. Examples of polymerizable monomers having functional groups capable of hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc., which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization. These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.

The molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer. Or it is preferable to adjust so that the streaming potential of a quaternary ammonium salt copolymer may become the value mentioned above. Or it is preferable to adjust so that IOB of a quaternary ammonium salt copolymer may become the value mentioned above. In particular, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and even more preferably 56 mol% or less. Specifically, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, More preferably, it is 32 mol% or more and 65 mol% or less, and more preferably 38 mol% or more and 56 mol% or less.

When the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, as the polycondensate, a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used. Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.

The above-described quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or copolymerization method of a vinyl polymerizable monomer. As the polymerization method, for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used. There are no particular limitations on the polymerization conditions, and the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.

The cationic polymer described in detail above is an example of the above-mentioned “preferable hemagglutinating agent 8”, and the effect thereof is Japanese Patent Application No. 2015-239286 and Japanese Patent Application Laid-Open No. 2016-107100 which is the Japanese publication of the application. And Examples 1 to 45 described in International Publication No. 2016/093233 pamphlet of the international application based on the priority claim.

In addition, as described above, the water-soluble hemagglutinating agent 8 provided in the napkin 1 is a composition containing a third component, for example, a solvent, a plasticizer, a fragrance, a skin care agent, etc. in addition to the cationic polymer (blood cell) It may be given in the form of a flocculant composition). In addition, components other than the cationic polymer that can be included in the hemagglutinating agent 8 can be used singly or in combination. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used. As a fragrance | flavor, the fragrance | flavor which has the green herbal-like fragrance described in patent 4776407, the extract of a plant, the extract of citrus fruits, etc. can be used. As the skin care agent, plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.

The proportion of the cationic polymer in the hemagglutinating agent composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less. For example, the proportion of the cationic polymer is preferably 1% by mass to 50% by mass, more preferably 3% by mass to 30% by mass, and even more preferably 5% by mass to 10% by mass. preferable. By setting the proportion of the cationic polymer in the hemagglutinating agent composition within this range, an effective amount of the cationic polymer can be imparted to the absorbent article.

As described above, in the napkin 1, the hemagglutinating agent 8 is disposed on the second sheet 5 as shown in FIG. The thickness of the second sheet 5 on which the hemagglutinating agent 8 is arranged is preferably 0.1 mm or more, particularly 0.3 mm or more, and preferably 1 mm or less, particularly 0.5 mm or less. More specifically, it is preferably 0.1 mm or more and 1 mm or less, particularly 0.3 mm or more and 0.5 mm or less in terms of obtaining an absorbent article that allows menstrual blood to pass through in a spot manner and has a good wearing feeling. . The thickness of the second sheet 5 is measured by the following method.

<Method for measuring thickness of second sheet>
The second sheet, which is a measurement object, is placed in a horizontal place so as not to be wrinkled or bent, and the thickness under a load of 5 cN / cm ² is measured. A thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) Was used for measuring the thickness in the present invention. At this time, a circular plate or a square plate (acrylic plate having a thickness of about 5 mm) in plan view is disposed between the tip of the thickness meter and the measurement portion of the measurement object, and the load is 5 cN / cm ² . Adjust the size of the plate so that

In the napkin 1, the second sheet 5 has a plurality of high-density portions 52 that are spaced apart from each other and have a higher density of constituent fibers than their adjacent portions, as shown in FIGS. Preferably, the high-density part 52 is formed from a compressed part in which the density of the constituent fibers is relatively increased by compression. Therefore, the second sheet 5 is divided into a high density portion 52 in which the density of the constituent fibers is increased by compression and a low density portion 53 that is an uncompressed portion other than the high density portion 52. The high density portion 52 can adopt various shapes such as a circle, an ellipse, a square, a rectangle, and a triangle when the second sheet 5 is viewed in plan from the skin facing surface side. Adopting a circular shape. The high density portion 52 has an area in plan view of preferably 0.3 mm ² or more, more preferably 0.5 mm ² or more, and preferably 2.0 mm ² or less. More preferably, it is 1.5 mm ² or less, specifically, 0.3 mm ² or more and 2.0 mm ² or less, more preferably 0.5 mm ² or more and 1.5 mm ² or less.

As shown in FIGS. 1 and 2, the high density portions 52 are arranged in a substantially staggered pattern in the napkin 1. Here, the staggered pattern refers to an arrangement in which the high-density portions 52 in each row are arranged at equal intervals, and the high-density portions 52 are shifted from each other by a half pitch between adjacent rows.
The number of arrangement per unit area of the high-density part 52 is preferably 15 pieces / cm ² or more, more preferably 20 pieces / cm ² or more, and 50 pieces / cm ² or less. It is more preferable that it is 40 pieces / cm ² or less, specifically, it is preferably 15 pieces / cm ² or more and 50 pieces / cm ² or less, and 20 pieces / cm ² or more and 40 pieces / cm ^2. More preferably, it is as follows.
The distance between adjacent adjacent high- density portions 52, 52 is preferably 0.5 mm or more, more preferably 0.8 mm or more, and preferably 2.0. More preferably, it is 5 mm or less, specifically 0.5 mm or more and 2.0 mm or less, and more preferably 0.8 mm or more and 1.5 mm or less.

In the napkin 1, the hemagglutinating agent 8 disposed on the second sheet 5 is present on the skin facing surface side and the non-skin facing surface side of the second sheet 5, as shown in FIG. The amount of hemagglutinating agent 8 contained in the second sheet 5 is preferably 0.1 g / m ² or more, more preferably 0.5 g / m ² or more, and 1.5 g / m ² or more. More preferably it is. Further, it is preferably 25 g / m ² or less, more preferably 15 g / m ² or less, and even more preferably 10 g / m ² or less. For example, the amount of hemagglutinating agent 8 in the second sheet 5 is preferably 0.1 g / m ² or more and 25 g / m ² or less, more preferably 0.5 g / m ² or more and 15 g / m ² or less, More preferably, it is 1.5 g / m ² or more and 10 g / m ² or less. By applying the hemagglutinating agent 8 to the second sheet 5 in an amount within this range, the excreted menstrual red blood cells can be effectively aggregated. It is particularly preferable that the hemagglutinating agent 8 is a cationic polymer and the amount of the cationic polymer contained in the second sheet 5 is in the above range.

Whether or not the hemagglutinating agent 8 is disposed on the second sheet 5 can be easily analyzed by those skilled in the art, such as a method of analyzing the extracted components after performing the extraction operation by exposing the second sheet to a solvent. For example, it can also be determined as follows.
Using an energy dispersive X-ray analyzer (EDX) attached to the scanning electron microscope (SEM), elemental analysis of each of the constituent fibers and the hemagglutinating agent 8 constituting the second sheet 5 is performed in advance. Next, a sample piece to be judged as to whether or not the hemagglutinating agent 8 is arranged is attached to an aluminum sample table using a double-sided carbon tape, and after performing platinum / vanadium coating as necessary, SEM observation is performed. The presence or absence of elements in the hemagglutinating agent 8 is confirmed using EDX (element analysis device) while enlarging. The measurement is performed at an acceleration voltage of 15 kV to 40 kV.

In the napkin 1, as shown in FIG. 4, the hemagglutinating agent 8 arranged in the second sheet 5 is present in the high-density part 52 and the low-density part 53, and is higher in density than the low-density part 53 side. Many exist on the 52 side. Here, “there are many” means the mass of the hemagglutinating agent 8 present per area of each of the high density portion 52 and the low density portion 53 in the second sheet 5, that is, each high density portion 52 and the low density portion 52. When the basis weight of the hemagglutinating agent 8 in the density part 53 is compared, it means that the basis weight of the hemagglutinating agent 8 on the one high density part 52 side is relatively large.

Further, whether or not the hemagglutinating agent 8 is present on the high density portion 52 side more than the low density portion 53 side is determined semi-quantitatively as follows.
A sample piece comprising a second sheet 5 having a high density portion 52 and a low density portion 53 and containing the hemagglutinating agent 8 is attached to an aluminum sample stage using a double-sided carbon tape, and platinum / After the vanadium coating is performed, the elements of the constituent fibers and the elements of the hemagglutinating agent 8 are mapped using EDX (element analyzer) while magnifying by SEM observation. The measurement is performed at an acceleration voltage of 15 kV to 40 kV. Then, comparing the mapping of the obtained element distribution, when the element mapping of the hemagglutinating agent 8 is observed more in the high-density portion 52 than in the low-density portion 53, the hemagglutinating agent 8 is reduced in the low-density portion. It is determined that there are more in the high density portion 52 than 53.

FIG. 4 shows an enlarged cross-sectional view of the absorber 4 in the cross-sectional view shown in FIG. In the napkin 1, one absorbent sheet constituting the absorbent body 4 has a superabsorbent polymer 41 dispersedly arranged in three dimensions and constituent fibers. The absorbent sheet has a polymer-rich region PT having a relatively high mass ratio of the superabsorbent polymer 41 to the total mass of the constituent fibers and the superabsorbent polymer 41 in a cross-sectional view, and the polymer-rich region. It has a fiber rich region FT that is relatively lower than PT. In the napkin 1, the polymer rich region PT and the fiber rich region FT are divided in the thickness direction of the absorbent sheet. The absorbent sheet has an integral structure in which the superabsorbent polymer 41 is contained inside the absorbent body 4. As the absorbent sheet, the adhesive force generated in the wet superabsorbent polymer 41 and a binder such as an adhesive or an adhesive fiber added separately, between the constituent fibers, or between the superabsorbent polymer 41 and the constituent fiber, A sheet or the like that is bonded between the two can be preferably used. In addition, an absorptive sheet | seat is an absorber currently shape | molded by the sheet form, and is generally distinguished from the absorbent body of the pile type structure which piled up the absorptive material. Typical examples of the absorbent sheet include those described in Japanese Patent No. 2963647 and those described in Japanese Patent No. 2955223.

As the superabsorbent polymer 41 possessed by the absorbent body 4, particles are generally used, but fibers may be used. When the particulate superabsorbent polymer is used, the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape. As the superabsorbent polymer, generally, a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof. As the polyacrylate and polymethacrylate, sodium salts can be preferably used. In addition, acrylic acid or methacrylic acid, maleic acid, itaconic acid, acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, styrenesulfonic acid, etc. It is also possible to use a copolymer obtained by copolymerizing the above-mentioned comonomer within a range that does not deteriorate the performance of the superabsorbent polymer.

Examples of the constituent fibers of the absorbent body 4 include synthetic fibers and cellulosic fibers. As a synthetic fiber, it is preferable that it is a thermoplastic fiber, for example. For example, the thermoplastic fiber is formed using a single fiber formed using a single synthetic resin such as polyethylene, polypropylene, polyester, polyurethane, or a synthetic resin such as a composite of two or more of these. A composite fiber is mentioned. Examples of the cellulosic fibers include crosslinked cellulose fibers (pulp fibers) obtained by crosslinking cellulose molecules between or between molecules with an appropriate crosslinking agent, or regenerated cellulose fibers such as rayon fibers having improved cellulose crystallinity. It is done.

In the napkin 1, the absorbent body 4 has a multilayer structure formed of an absorbent sheet as shown in FIGS. Here, the formed multilayer structure may be formed by overlapping a plurality of absorbent sheets, or may be formed by folding a single absorbent sheet. However, it may be formed by combining these. In the napkin 1, the absorbent body 4 includes, as shown in FIGS. 3 and 4, a central absorbent sheet 402 formed of an absorbent sheet on the excretory part facing portion B of the wearer when worn, and a central absorbent sheet 402. It is comprised with the main body absorbent sheet 401 to cover. That is, the absorbent body 4 of the napkin 1 is formed with a multilayer structure including the main body absorbent sheet 401 and the central absorbent sheet 402, and the middle and high portions 403 are formed in the excretory part facing part B. The multilayer structure of the absorbent body 4 of the napkin 1 has a structure in which a central absorbent sheet 402 is included in the folded structure of one main body absorbent sheet 401, and the central absorbent sheet 402 is formed in the middle and high portions 403. It is arranged.

Preferably, in the napkin 1, as shown in FIG. 3 and FIG. 4, the main body absorbent sheet 401 is composed of one sheet having a length (width) in the lateral direction Y longer than that of the napkin 1, and the main body absorbent sheet 401 Of the absorbent sheet 401 is folded back to the back sheet 3 side to form a two-layer structure, and both side edges along the vertical direction X are overlapped at the center in the horizontal direction Y, The outer shape is formed. Thus, the main body absorbent sheet 401 which forms a two-layer structure has the surface side absorbent sheet 401a by the side of the surface sheet 2, and the back surface side absorbent sheet 401b by the side of the back sheet 3. The central absorbent sheet 402 is composed of a single sheet having a rectangular shape in plan view, and has a three-layer structure in which the central absorbent sheet 402 is folded in three in the lateral direction Y. When the central absorbent sheet 402 has a three-layer structure, in the two fold lines crossing the central absorbent sheet 402 in the longitudinal direction X, the second fold line counted from the free end in the lateral direction Y is used. Bend to the back sheet 3 side, and then bend to the top sheet 2 side at the first fold line counted from the free end in the lateral direction Y so that the free end in the lateral direction Y is arranged inside the three-layer structure Fold it in a spiral. Thus, the central absorbent sheet 402 that forms a three-layer structure folded in a spiral shape includes an upper absorbent sheet 402a on the front surface side absorbent sheet 401a side and a lower absorbent sheet on the back surface side absorbent sheet 401b side. 402b and an intermediate absorbent sheet 402c between the sheets 402a and 402b. The middle-high portion 403 is formed by sandwiching a sheet having a three-layer structure including an upper absorbent sheet 402a, an intermediate absorbent sheet 402c, and a lower absorbent sheet 402b between the front side absorbent sheet 401a and the rear side absorbent sheet 401b. Has been. The middle-high part 403 is formed only in the excretion part facing part B, and is not formed in the front part A and the rear part C. As shown in FIG. 3, the number of laminated absorbent sheets constituting the absorbent body 4 around the middle-high portion 403 is two, whereas the number of laminated absorbent sheets constituting the absorbent body 4 in the middle-high portion 403. However, the number of laminated sheets is large and the thickness is large. For this reason, the middle-high part 403 is a raised part that protrudes from the excretory part facing part B to the topsheet 2 side (skin facing side of the napkin 1).

The thickness per absorbent sheet is preferably 0.1 mm or more, particularly 0.3 mm or more, and preferably 2 mm or less, particularly 1.5 mm or less. More specifically, it is 0.1 mm or more and 2 mm or less, particularly 0.3 mm or more and 1.5 mm or less, and the absorbent article 4 absorbs menstrual blood spotwise and obtains an absorbent article having a good wearing feeling. It is preferable from the point.

The absorber 4 has a thickness at the middle-high portion 403 of preferably 0.7 mm or more, more preferably 1 mm or more, preferably 5 mm or less, more preferably 4 mm or less, more specifically preferably It is 0.7 mm or more and 5 mm or less, More preferably, it is 1 mm or more and 4 mm or less. By setting the thickness of the mid-high portion 403 in such a range, it becomes easy to achieve both a good wearing feeling and high absorption performance in the excretory portion facing portion B where the mid-high portion 403 is formed. Moreover, when the absorbent article is provided with a wing part like the napkin 1 of this embodiment, it becomes easy to suppress the twist of the absorber in an excretion part opposing part at the time of mounting | wearing. The thickness of the absorber other than the middle-high portion 403 is preferably 0.3 mm or more, more preferably 0.5 mm or more, and preferably 3 mm or less, more preferably 2.5 mm or less, More specifically, it is preferably 0.3 mm or more and 3 mm or less, more preferably 0.5 mm or more and 2.5 mm or less. This range is preferable from the viewpoint of enhancing the high absorption performance and the ability to follow the wearer's movement. In addition, the thickness of an absorber and an absorptive sheet is measured by the following method.

<Measurement method of thickness of absorbent sheet and absorber>
The absorbent sheet or absorbent body, which is the measurement object, is placed in a horizontal place so as not to be wrinkled or bent, and the thickness under a load of 5 cN / cm ² is measured. A thickness meter PEACOCK DIAL UPRIGHT GAUGES R5-C (manufactured by OZAKI MFG.CO.LTD.) Was used for measuring the thickness in the present invention. At this time, a circular plate or a square plate (acrylic plate having a thickness of about 5 mm) in plan view is disposed between the tip of the thickness meter and the measurement portion of the measurement object, and the load is 5 cN / cm ² . Adjust the size of the plate so that

Further, the absorbent body 4 has an uneven structure on at least the skin facing surface of the absorbent body 4. In the napkin 1, as shown in FIG. 4, the absorbent body 4 made of an absorbent sheet includes a portion that is used with the fiber-rich region FT disposed on the skin facing surface side. Preferably, in the napkin 1, the surface side absorbent sheet 401a constituting the main body absorbent sheet 401 having a two-layer structure is used with the fiber rich region FT disposed on the skin facing surface side. The skin facing surface 401a has an uneven structure. More preferably, the absorbent body 4 of the napkin 1 has a slit 44 for diffusing blood, and the skin 44 has an uneven structure due to the slit 44.

In the napkin 1, a slit 44 extending in parallel to the longitudinal direction X is provided in the excretory part facing part B of the absorber 4 as shown in FIGS. The slit 44 makes it easy for menstrual blood that has reached the absorber 4 to be diffused in the longitudinal direction X and also to penetrate in the thickness direction of the absorber 4. In the napkin 1, as shown in FIG. 2, the slits 44 extending in the vertical direction X have slit regions 44 </ b> S formed in a state of being dispersed in both the vertical direction X and the horizontal direction Y. As shown in FIG. 2, the slit region 44 </ b> S in which the plurality of slits 44 are arranged extends not only to the excretory part facing part B but also to a part of the front part A and a part of the rear part C. That is, the slit 44 exists at least in the excretory part facing part B, and an area including the slit 44 located in the excretion part facing part B is referred to as a slit area 44S.

The slit 44 only needs to penetrate at least the surface-side absorbent sheet 401a on the most skin-facing surface side from the viewpoint of making at least the skin-facing surface of the absorbent body 4 into an uneven structure. The absorber 4 having a multilayer structure formed of a sheet penetrates all the layers in the thickness direction. Preferably, in the napkin 1, in the excretion part facing part B, the slit 44 includes five laminated sheets constituting the middle-high part 403, that is, the surface side absorbent sheet 401a, the upper absorbent sheet 402a, and the intermediate absorbent sheet. It penetrates all the sheets 402c, the lower absorbent sheet 402b, and the rear absorbent sheet 401b. Moreover, in the napkin 1, the slit 44 penetrates the front surface side absorbent sheet 401a and the back surface side absorbent sheet 401b in a part of the front part A and a part of the rear part C.

In the napkin 1, the slits 44 are arranged in the slit region 44S in such a manner that each slit 44 is distributed in both the vertical direction X and the horizontal direction Y, and four or more slits are distributed in the central slit region 44S1. Preferably it is. The central slit region 44S1 is a region overlapping with the central absorbent sheet 402 in the slit region 44S.
In the central slit region 44S1, it is preferable that three or more slit rows are formed in the longitudinal direction X, more preferably four rows or more, and still more preferably five rows or more. Further, the number of slits 44 spaced apart in the lateral direction Y included in each slit row is preferably 2 or more, and more preferably 3 or more.
In the longitudinal direction X of the slit region 44S, in addition to the slit rows included in the central slit region 44S1, it is preferable to have one row or two or more slit rows before and after the longitudinal direction X of the central slit region 44S1.

The width W44 (see FIG. 2) when each slit 44 is viewed in plan is preferably 0.1 mm or more, more preferably 0.2 mm or more, more preferably 1 mm or less, still more preferably 0.8 mm or less, 0.1 mm or more and 1 mm or less are preferable, and 0.2 mm or more and 0.8 mm or less are more preferable.
The length (length in the longitudinal direction) L44 (see FIG. 2) when the slit 44 in the slit region 44S is viewed in plan is preferably 10 mm or more, more preferably 15 mm or more, and preferably 35 mm or less, more preferably. Is 25 mm or less, preferably 10 mm or more and 35 mm or less, more preferably 15 mm or more and 25 mm or less.
The interval (width direction interval) D44 between the slits 44 in the same slit row in the slit region 44S is preferably 3 mm or more, more preferably 7 mm or more, preferably 20 mm or less, more preferably 15 mm or less, and preferably Is from 3 mm to 20 mm, more preferably from 7 mm to 15 mm.

Moreover, in the napkin 1, as shown in FIG.3 and FIG.4, the skin side adhesive agent 11U is distribute | arranged between the surface sheet 2 and the second sheet | seat 5, and the skin opposing surface of the surface sheet 2 and the second sheet | seat 5 is a part. Fixed. In the napkin 1, the skin side adhesive 11U is applied in a spiral shape that is long in the vertical direction X, for example, using a spray gun, and is applied intermittently in the horizontal direction Y. In addition to the spiral shape, the coating shape may be a long Ω (omega) shape in the vertical direction X. The basis weight of the skin side adhesive 11U is 1 g / m ² or more, preferably 1.5 g / m ² or more, and 10 g / m ² or less, preferably 5 g / m ² or less, more specifically. It is preferably 1 g / m ² or more and 10 g / m ² or less, and more preferably 1.5 g / m ² or more and 5 g / m ² or less.

In the napkin 1, the position where the hemagglutinating agent 8 is arranged and the position where the skin-side adhesive 11U is arranged overlap in a plan view as shown in FIG. Preferably, in the napkin 1, the position of the hemagglutinating agent 8 disposed on the second sheet 5 and the skin side disposed between the top sheet 2 and the second sheet 5 and partially fixing the top sheet 2 and the second sheet 5 The position of the adhesive 11U overlaps. In the napkin 1, the hemagglutinating agent 8 arranged on the second sheet 5 is present more on the high density part 52 side arranged in a staggered manner than the low density part 53 side, and the skin side adhesive 11U is It is coated in a spiral shape between the top sheet 2 and the second sheet 5. Therefore, as shown in FIG. 1, in a plan view, a portion where the plurality of zigzag high-density portions 52 of the second sheet 5 overlap with the skin-side adhesive 11 </ b> U applied in a spiral shape. The position at which the hemagglutinating agent 8 present in the high-density portion 52 is disposed and the position at which the skin-side adhesive 11U is disposed overlap each other.

Moreover, in the napkin 1, as shown in FIG.3 and FIG.4, the non-skin side adhesive agent 11D is distribute | arranged between the second sheet | seat 5 and the absorber 4, and the non-skin opposing surface of the second sheet | seat 5 and the absorber 4 are provided. Is partially fixed. In the napkin 1, the non-skin-side adhesive 11D is applied in a spiral shape that is long in the vertical direction X using, for example, a spray gun, and is intermittently applied in the horizontal direction Y. In addition to the spiral shape, the coating shape may be a long Ω (omega) shape in the vertical direction X. The basis weight of the application of the non-skin side adhesive 11D is 1 g / m ² or more, preferably 1.5 g / m ² or more, and 10 g / m ² or less, preferably 5 g / m ² or less, more specifically. Is preferably 1 g / m ² or more and 10 g / m ² or less, more preferably 1.5 g / m ² or more and 5 g / m ² or less.

In the napkin 1, the position where the hemagglutinating agent 8 is arranged and the position where the non-skin-side adhesive 11D is arranged overlap in a plan view as shown in FIG. Preferably, in the napkin 1, the position of the hemagglutinating agent 8 disposed on the second sheet 5 and the surface side absorbent sheet 401 a disposed between the second sheet 5 and the absorbent body 4 and the second sheet 5 and the absorbent body 4 are provided. The position of the non-skin side adhesive 11D to be partially fixed overlaps. In the napkin 1, the hemagglutinating agent 8 arranged on the second sheet 5 is present more on the high density portion 52 side arranged in a staggered manner than the low density portion 53 side, and the non-skin side adhesive 11D is The second sheet 5 and the surface side absorbent sheet 401a of the absorbent body 4 are spirally coated. Therefore, as shown in FIG. 1, the plurality of staggered high-density portions 52 of the second sheet 5 and the non-skin-side adhesive 11 </ b> D coated in a spiral shape overlap each other in plan view. The position where the hemagglutinating agent 8 which has a part and exists in the high-density part 52 abundantly overlaps with the position where the non-skin side adhesive 11D is arranged.

The forming material of each component of the napkin 1 of the present embodiment described above will be described.

As the surface sheet 2, a single layer or multilayered nonwoven fabric, an apertured film, or the like can be used, but a surface sheet made of a nonwoven fabric treated with a hydrophilizing agent can be preferably used. As the hydrophilizing agent, various materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation. In the napkin 1, a sheet having a concavo-convex structure shown in FIG. 7 is used. In FIG. 5, the main part of the skin facing surface of the topsheet 2 in the napkin 1 is shown enlarged. On the skin facing surface 2a of the top sheet 2 (skin facing surface of the napkin 1), depressions 20 extending in the direction intersecting the vertical direction X and the horizontal direction Y (that is, the diagonal direction) are formed in a diagonal lattice shape. The top sheet 2 is partitioned into a large number of regions by the recess 20, and a large number of partitioned regions 22 are formed. In the embodiment shown in FIG. 5, the recess 20 is formed over the entire surface sheet 2. It may replace with this and you may form the hollow part 20 in the excretion part opposing part B at least. Note that the X direction in FIG. 5 is the same direction as the direction (CD) orthogonal to the sheet flow direction at the time of manufacturing the top sheet, and is also the same as the longitudinal direction X (see FIG. 1) of the napkin 1. Further, the Y direction in FIG. 5 is the same direction as the sheet flow direction (MD) during the production of the surface sheet, and is also the same as the lateral direction Y (see FIG. 1) of the napkin 1.

The surface sheet 2 will be further described. The surface sheet 2 is made of a fiber sheet such as a nonwoven fabric having a single layer structure or a multilayer structure, for example, and the entire area of the skin facing surface 2a is formed in an oblique lattice shape as shown in FIG. It has a concave-convex shape having a large number of concave portions 20 and a plurality of convex portions 21 surrounded by the concave portions 20. On the other hand, the non-skin facing surface 2b of the topsheet 2 does not substantially have an uneven shape and is substantially flat.

The hollow portion 20 is formed by press-bonding or bonding the constituent fibers of the surface sheet 2 made of a fiber sheet. Examples of means for crimping the fiber include embossing such as pressing with or without heat, and ultrasonic pressing. As a result, in the surface sheet 2, the density of the recessed portions 20 is higher than the density of the convex portions 21. Due to this, when the external force is applied to the top sheet 2, the recessed portion 20 easily acts as a flexible shaft for deformation. The recess 20 in the topsheet 2 according to the present embodiment is formed by subjecting a fiber web formed by a card method to hot embossing. In the hollow part 20, the heat-fusible fiber which is the constituent fiber of the surface sheet 2 or the nonwoven fabric which comprises it is integrated by heat fusion. The heat-fusible fiber in the hollow part 20 does not maintain the form of the fiber because the heat-fusion component is melted.

In the surface sheet 2, the recess 20 is formed only in the surface sheet 2, and is not formed in the absorber 4 disposed adjacent to the surface sheet 2 below the surface sheet 2. Therefore, the topsheet 2 and the absorber 4 are not joined via the recess 20.

The recess 20 is preferably linear. Here, “linear” means that the shape of the depression 20 is not limited to a straight line as shown in FIG. 5 in a plan view, but includes a curve, and each line may be a continuous line, or may be a rectangle, square, rhombus in a plan view. In addition, a large number of concave portions (embossed portions) such as a circle and a cross may be connected substantially without being spaced apart to form a continuous line as a whole. “Substantially without an interval” means that the interval between adjacent recesses is within 5 mm.

The depression 20 is formed in an oblique lattice shape as shown in FIG. More specifically, the topsheet 2 is formed as the depressions 20 in parallel with each other and a plurality of first linear depressions 20a formed at a predetermined interval and in parallel with each other at a predetermined interval. In addition, a plurality of second linear depressions 20b are formed, and the first linear depressions 20a and the second linear depressions 20b intersect each other at a predetermined angle. Each of the first linear depression 20a and the second linear depression 20b extends linearly in a direction that intersects the vertical direction X and the horizontal direction Y (that is, an oblique direction). The width of the first linear depression 20a and the width of the second linear depression 20b may be the same or different. The interval between the first linear depressions 20a and the interval between the second linear depressions 20b may be the same or different.

Each partition region 22 is a region surrounded by a linear depression 20 and has a rhombus shape in plan view. Area of each divided area 22 is preferably, for example, 0.25 cm ² or more 2 cm ² or less. The partition region 22 may have a rhombus shape that is longer in the horizontal direction Y than in the vertical direction X in plan view. Or conversely, it can also be made into a rhombus shape longer in the vertical direction X than in the horizontal direction Y. When the partition region 22 has a shape that is long in the lateral direction Y of the napkin 1, the topsheet 2 on which a large number of the recessed portions 20 are formed retains high rigidity in the lateral direction Y. This effectively prevents twisting and wrinkling in the state in which the napkin 1 is attached. When the napkin 1 is worn, wrinkles or wrinkles are mainly caused by the napkin 1 sandwiched between the thighs of the wearer being pressed from the lateral direction Y by the thighs. However, if the rigidity is maintained in the lateral direction Y, the shape of the napkin 1 is easily maintained even when pressed from the lateral direction Y, and twisting and wrinkles are less likely to occur.

Each partition region 22 is formed with a convex portion 21 that protrudes relatively to the hollow portion 20 surrounding the partition region 22, and each partition region 22 has a top portion 21 a on the skin facing surface 2 a side. It has a shape. The top portion 21 a of the convex portion 21 is located at the center of the partition region 22. The inside of the convex portion 21 is filled with the constituent fibers of the topsheet 2. In the present invention, a hollow portion other than a linear shape is not excluded, but from the viewpoint of forming a good convex portion 21, a linear hollow portion is preferable.

Thus, the contact area with the wearer's skin of the napkin 1 reduces because the hollow part 20 and the convex part 21 are alternately arrange | positioned in the vertical direction X and the horizontal direction Y of the surface sheet 2, respectively. This effectively prevents stuffiness and rash. Moreover, the convex part 21 (partition area | region 22) is surrounded by the hollow part 20, and since it has the closed shape in planar view, compared with the case where the convex part 21 is not surrounded by the hollow part 20, Since the constituent fibers in the convex portion 21 are easily stretched in the thickness direction of the top sheet 2, the thickness of the convex portion 21 is increased, thereby 1) the liquid can permeate quickly and the liquid residue is small, and the top sheet 2. 2) Since the convex portions 21 are formed in a regular pattern, the visual impression is improved, and so on.

In addition, it replaces with the thing of the structure mentioned above as a surface sheet of a concavo-convex structure, the surface sheet of a concavo-convex structure which has a hollow convex part, and the collar part from which a convex part and a recessed part each extend in the vertical direction or the horizontal direction of the napkin 1 And a surface sheet that is a groove. However, from the viewpoint of menstrual blood absorption, the above-described solid surface uneven sheet is preferable.

In addition, as the back surface sheet 3, various things conventionally used for absorbent articles, such as a sanitary napkin, can be used without a restriction | limiting especially, A moisture-permeable resin film and a moisture-impermeable resin film can be used. .

The second sheet 5 is preferably made of a hydrophilic nonwoven fabric or a hydrophilic fiber assembly. Examples of the nonwoven fabric include air-through nonwoven fabric, point bond nonwoven fabric, resin bond nonwoven fabric, spunlace nonwoven fabric, and airlaid nonwoven fabric.
From the viewpoint of quickly drawing menstrual blood during use of the napkin 1, the second sheet 5 preferably has a basis weight that is higher than the basis weight of the top sheet 2, and specifically, preferably 10 g / m ² or more and 50 g / m ^2. m ² or less, more preferably 15 g / m ² or more and 40 g / m ² or less.

As the skin-side adhesive 11U and the non-skin-side adhesive 11D, various kinds of materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation. For example, a hot melt adhesive is preferable. Used.
Moreover, in the napkin 1, it is preferable that the absorber 4 and the back surface sheet 3 are fixed by applying an adhesive. The adhesive can be applied using a known means such as a slot coat gun, a spiral spray gun, a spray gun, or a dot gun. In the napkin 1, the adhesive can be applied in a spiral shape using a spiral spray gun. preferable. As the adhesive to be applied, for example, a hot melt adhesive is preferably used. The application amount of the hot melt adhesive is preferably 1.5 g / m ² or more and 10 g / m ² or less.

The operational effect and estimation mechanism of the napkin 1 described above will be described.
In the napkin 1, as shown in FIG. 4, a water-soluble hemagglutinating agent 8 is present in the second sheet 5. Therefore, during use of the napkin 1, when menstrual blood comes into contact with the water-soluble hemagglutinating agent 8, the hemagglutinating agent 8 is eluted and is disposed at a position overlapping the position where the hemagglutinating agent 8 is disposed. Fixation between the top sheet 2 and the second sheet 5 by the skin-side adhesive 11U is weakened, and a space is easily formed between the top sheet 2 and the second sheet 5. Thus, when a space is formed between the top sheet 2 and the second sheet 5, menstrual blood can be sufficiently temporarily stored in this space, body fluid can be absorbed quickly, and the body fluid can be absorbed on the skin side of the wearer. It is possible to effectively prevent the return to.

Moreover, in the napkin 1, as shown in FIG. 4, the non-skin-side adhesive 11D is disposed between the second sheet 5 and the absorbent body 4, and the non-skin facing surface of the second sheet 5 and the absorbent body 4 are partially separated. It is fixed to. Therefore, during use of the napkin 1, when menstrual blood comes into contact with the water-soluble hemagglutinating agent 8, the hemagglutinating agent 8 is eluted and is disposed at a position overlapping the position where the hemagglutinating agent 8 is disposed. Fixing by the non-skin-side adhesive 11D is weakened, and a space is easily formed between the second sheet 5 and the absorber 4. As described above, when a space is formed between the second sheet 5 and the absorbent body 4, menstrual blood can be sufficiently temporarily stored in this space, body fluid can be quickly absorbed, and body fluid leakage is effectively prevented. Can be prevented. Further, when menstrual blood comes into contact with the water-soluble hemagglutinating agent 8, menstrual blood is separated into red blood cells and plasma, and the aggregate formed by the aggregation of red blood cells is the space between the second sheet 5 and the absorber 4. It is easy to be caught with. The separated plasma is efficiently absorbed by the superabsorbent polymer 41 of the absorbent body 4 located on the non-skin facing surface side of the second sheet 5. Therefore, it is not necessary to use a nonwoven fabric or the like that is thicker than the nonwoven fabric that is generally used as the second sheet, so that the feeling of wearing is improved and retention of menstrual blood hardly occurs.

Further, in the napkin 1, as shown in FIG. 4, the skin facing surface of the absorbent body 4 has an uneven structure by the slits 44. Therefore, during use of the napkin 1, the capacity of the space between the second sheet 5 and the absorbent body 4 formed by the elution of the water-soluble hemagglutinating agent 8 is easily formed. Therefore, menstrual blood can be more fully temporarily stored in a space having a large capacity, body fluid can be absorbed more quickly, and leakage of body fluid can be more effectively prevented. Further, in the napkin 1, the surface side absorbent sheet 401a constituting the main body absorbent sheet 401 having a two-layer structure is used with the fiber rich region FT disposed on the skin facing surface side, and the polymer rich region PT is opposed to the non skin. Used on the surface side. Therefore, the plasma separated by the hemagglutinating agent 8 is efficiently absorbed by the superabsorbent polymer 41 in the polymer-rich region PT disposed on the non-skin facing surface side of the absorber 4, and the body fluid can be absorbed more quickly.

Moreover, in the napkin 1, the second sheet 5 has a plurality of high density portions 52 in which the density of the constituent fibers is relatively increased by compression, as shown in FIGS. Therefore, during use of the napkin 1, menstrual blood easily collects in the high density portion 52, and the space between the top sheet 2 and the second sheet 5 formed by the elution of the water-soluble hemagglutinating agent 8 is eliminated. A large capacity is easily formed. Therefore, menstrual blood can be more fully temporarily stored in a space having a large capacity, body fluid can be absorbed more quickly, and leakage of body fluid can be more effectively prevented.

Further, in the napkin 1, as shown in FIG. 4, the hemagglutinating agent 8 disposed on the second sheet 5 is present in the high density portion 52 and the low density portion 53, and is higher than the low density portion 53 side. Many exist on the density part 52 side. Therefore, during use of the napkin 1, menstrual blood easily collects in the high density portion 52, and the surface sheet 2 and the second sheet formed by the elution of the water-soluble hemagglutinating agent 8 present in a large amount in the high density portion 52. The capacity of the space between the sheet 5 is easily formed large. Accordingly, menstrual blood can be further sufficiently temporarily stored in a space having a large capacity, and body fluid can be absorbed quickly and repeatedly.

In the napkin 1, as shown in FIG. 2, the width of the second sheet 5 (the length in the lateral direction Y) is shorter than the width of the absorber 4 (the length in the lateral direction Y). Therefore, during use of the napkin 1, even if a large external force is generated from both legs, the hemagglutinating agent 8 disposed on the second sheet 5 can be prevented from adhering to the skin.

As mentioned above, although this invention was demonstrated based on the preferable embodiment, the sanitary absorbent article of this invention is not restrict | limited to the napkin 1 of the said embodiment at all, and can be changed suitably.
For example, in the napkin 1, as shown in FIGS. 3 and 4, the absorbent body 4 has an uneven structure on the skin facing surface due to the slit 44, but the skin facing surface has an uneven structure without using the slit 44. It may be. For example, you may use the absorber 4 with which the skin opposing surface as shown in FIG. 6 became uneven structure. The absorbent body 4 shown in FIG. 6 has a raised portion 45 that is raised on the skin facing surface side at the central portion CT in the lateral direction Y in the excretory portion facing portion B, and a peripheral portion 46 that surrounds the raised portion 45. A plurality of small absorbing portions 48 divided by a plurality of vertical groove portions 471 extending in the vertical direction X and a plurality of horizontal groove portions 472 extending in the horizontal direction Y are formed in the raised portion 45 and the peripheral portion 46. The small absorbent portion 48 is a portion in which the basis weight of the forming material of the absorbent body 4 is relatively higher than the bottom portions of the vertical groove portion 471 and the horizontal groove portion 472, and the bottom portions of the vertical groove portion 471 and the horizontal groove portion 472 are absorbed. The basis weight of the forming material of the body 4 is a portion having a relatively low basis weight as compared with the small absorbing portion 48. The raised part 45 is pressed in the process of manufacturing the absorber 4 of FIG. The pressure at the time of pressing the raised portion 45 concentrates on the thick raised portion 45, and the thin low-basis weight portion 43 is not compressed by the press and is not compressed. In this way, in the raised portion 45, only the high basis weight portion 42 is compressed, so that the high basis weight portion 42 is designed so that the density of the absorbent member is increased with respect to the low basis weight portion 43. Also, in the peripheral portion 46 other than the raised portion 45, in the step of manufacturing the absorbent body 4 in FIG. 6, it is pressed in a step different from the step of pressing the raised portion 45, and the peripheral portion 46 has a high basis weight portion. The high basis weight part 42 is designed so that the density of the absorbent member is increased with respect to the low basis weight part 43 by compressing only 42.

As shown in FIG. 7A, the absorbent body 4 shown in FIG. 6 described above includes a stacking recess 411 on the outer peripheral surface and rotates in one direction R, and the outer periphery of the stacking drum 412. It can be manufactured using a fiber stacking device provided with a duct (not shown) for supplying the core material in a scattered state on the surface.
A plurality of stacking recesses 411 are formed at regular intervals in the circumferential direction of the outer peripheral surface of the fiber stacking drum 412. The bottom surface 413 of the accumulation recess 411 is made of a mesh plate or the like and has a large number of pores functioning as suction holes.

Further, as shown in FIG. 7A, a single concave portion 414 for forming the raised portion 45 is formed at the center of the bottom surface 413 of one concave portion for accumulation 411. Further, a breathable member 415 for forming the vertical groove portion 471 and the horizontal groove portion 472 is arranged on the bottom surface 414b of the concave portion 414 and the bottom surface 413 of the peripheral region of the concave portion 414 for forming the peripheral portion 46. The air-impermeable member 415 is disposed at a position corresponding to the longitudinal groove portion 471 and the lateral groove portion 472 and is fixed so as to protrude from the bottom surface 413 of the accumulation recess 411 and the bottom surface 414b of the recess 414. The non-breathable member 415 may be a non-breathable member, and is made of, for example, metal, plastic, ceramic, or the like.

By supplying the core material 400 in which the water-absorbing polymer and the pulp fiber are mixed into the duct while sucking from the bottom surface 413 of the accumulation concave portion 411, similarly to the known fiber pile device including the fiber pile drum, As shown in FIG. 7B, the material is deposited in a predetermined shape in the accumulation recess 411. The absorbent body 4 as shown in FIG. 6 can be manufactured by releasing the deposit 416 from the accumulation recess 411. In addition, the absorber 4 shown in FIG. 6 manufactured in this way may be wrapped with a core wrap sheet subjected to a creping process to be described later.

The napkin 1 shown in FIG. 8 provided with the absorber 4 shown in FIG. 6 can have the same effects as the napkin 1 shown in FIGS. 3 and 4.
In addition, according to the napkin 1 shown in FIG. 8, the capacity of the space between the second sheet 5 and the absorber 4 formed by the elution of the water-soluble hemagglutinating agent 8 is easily formed. Therefore, menstrual blood can be further sufficiently temporarily stored in the space formed with a large capacity by the concave portion of the absorbent body 4 and can be quickly absorbed by the convex portion, so that body fluid can be quickly and repeatedly absorbed.

Moreover, in the napkin 1, as shown in FIG.3 and FIG.4, although the absorber 4 is formed with the absorptive sheet and the skin opposing surface has the uneven structure by the slit 44, it is formed with an absorptive sheet. The absorbent core may be an absorbent core that is not formed, specifically, a pile-type absorbent core and a core wrap sheet that wraps the absorbent core. In order to make the skin-facing surface of the absorbent body formed by the absorbent core and the core wrap sheet have a concavo-convex structure, it is preferable that wrinkles are formed on the surface, and more specifically, creping has been performed. It is preferable to use a core wrap sheet. Preferably, the core wrap sheet to be used has creped wrinkles extending in the vertical direction X, and a large number of fine wrinkled wrinkles are formed at least on the entire surface facing the skin. As a raw material for the core wrap sheet, paper or a hydrophilic nonwoven fabric is preferably used. Examples of the paper include paper made by a wet papermaking method mainly composed of wood pulp fibers. Examples of the hydrophilic nonwoven fabric include air-through nonwoven fabric, point bond nonwoven fabric, spunlace nonwoven fabric, spunbond nonwoven fabric, and spunbond-meltblown-spunbond (SMS) nonwoven fabric. The basis weight of the nonwoven fabric is preferably 10 to 100 g / m ² , more preferably 15 to 60 g / m ² .

Creping applied to the core wrap sheet is performed by changing the transport speed using a general doctor blade. Specifically, the crepe rate of the core wrap sheet is preferably 3% or more and 25% or less, and more preferably 5% or more and 20% or less. The crepe rate can be evaluated by the following measuring method. The following measurement is performed at 23 ± 2 ° C. and a relative humidity of 50 ± 5%. Before the measurement, the sample is stored in the same environment for 24 hours or more.

<Measurement method of crepe rate>
Measured by the underwater elongation method. A core wrap sheet is cut into a size of 100 mm × 100 mm to prepare a measurement sample, the measurement sample is immersed in water and then pulled up, and the crepe rate is calculated from the amount of dimensional change according to the following equation.

Crepe rate (%) = ((dimension after being immersed in water) / (dimension before being immersed in water) -1) × 100
The measurement is performed 5 times (n = 5), the values at each of the upper and lower points are deleted, and the average value of the remaining three points is taken as the crepe rate.

In addition, as described above, when the absorbent body 4 is an absorbent body formed of a pile-type absorbent core and a core wrap sheet that wraps the absorbent core, the absorption from the core wrap sheet on the top sheet 2 side. The skin-facing surface of the absorbent body 4 may have a concavo-convex structure by pin embossing toward the conductive core.

In the napkin 1, as shown in FIG. 4, the hemagglutinating agent 8 is present only in the second sheet 5, but may be present not only in the second sheet 5 but also in the absorber 4. When the hemagglutinating agent 8 is present in the absorbent body 4, it is present in the main body absorbent sheet 401 that forms a two-layer structure including the front side absorbent sheet 401 a adjacent to the second sheet 5 and the back side absorbent sheet 401 b. It is preferable. When the hemagglutinating agent 8 is present in the main body absorbent sheet 401, the hemagglutinating agent 8 is present in the polymer rich region PT and the fiber rich region FT, and is opposed to the skin more than the polymer rich region PT on the non-skin facing surface side. It is preferable that many exist in the fiber rich region FT on the surface side.

In the napkin 1, as shown in FIG. 2, the second sheet 5 has the high-density portion 52 in which the density of the constituent fibers is relatively increased by compression, but has the high-density portion 52. It does not have to be.

Further, as shown in FIG. 4, the absorbent sheet constituting the absorbent body 4 is formed of a two-layer region of a polymer rich region PT and a fiber rich region FT, but the polymer rich region PT and the fiber rich region FT It may not be formed, and may be formed of three or more layers having a polymer rich region PT and a fiber rich region FT.

Furthermore, regarding the compressed groove 9, instead of the form of the napkin of the present embodiment, the longitudinal groove extending in the longitudinal direction X while forming the convex curved shape in the lateral direction Y inward in the excretion part facing part B. The groove shape in the front portion A and the rear portion C may be a straight groove shape or a compressed groove shape that is a concave curve shape inward in the lateral direction Y.

In addition, the sanitary absorbent article for absorbing menstrual blood of the present invention may be a panty liner (origin sheet) or the like in addition to a sanitary napkin.

The following sanitary absorbent articles are further disclosed with respect to the embodiment of the present invention described above.

<1>
Physiological device comprising an absorbent body containing a superabsorbent polymer, a top sheet and a back sheet sandwiching the absorbent body, and a second sheet composed of a non-woven fabric disposed between the top sheet and the absorbent body In the absorbent article, the second sheet includes a water-soluble hemagglutinating agent, and a skin-side adhesive is disposed between the top sheet and the second sheet, and the top sheet and the second sheet Physiologically fixed to the skin-facing surface, and the position where the hemagglutinating agent is disposed and the position where the skin-side adhesive is disposed overlap in a plan view of the absorbent article Absorbent articles.
<2>
A non-skin-side adhesive is disposed between the second sheet and the absorbent body, the non-skin facing surface of the second sheet and the absorbent body are partially fixed, and the absorbent article is viewed in plan view. The sanitary absorbent article according to <1>, wherein a position where the hemagglutinating agent is disposed overlaps a position where the non-skin side adhesive is disposed.
<3>
The absorbent article according to <1> or <2>, wherein at least the skin-facing surface of the absorbent body has an uneven structure.
<4>
The sanitary absorbent article according to any one of <1> to <3>, wherein the second sheet has a plurality of high-density portions in which constituent fibers spaced apart from each other have a high density.
<5>
The second sheet is divided into the high density part and a low density part other than the high density part, and the hemagglutinating agent is present in the high density part and the low density part, and the low density part The sanitary absorbent article according to any one of <1> to <4>, which is present more on the high-density part side than on the side.
<6>
The sanitary absorbent article according to any one of <1> to <5>, wherein the width of the second sheet is shorter than the width of the absorber.
<7>
The sanitary absorption according to any one of <1> to <6>, wherein the second sheet on which the hemagglutinating agent is disposed has a thickness of 0.1 mm to 1 mm, preferably 0.3 mm to 0.5 mm. Sex goods.
<8>
The high density portion of the second sheet is any one of <5> to <7>, wherein the shape of the second sheet when viewed from the skin-facing surface side is a circle, an ellipse, a square, a rectangle, or a triangle. The sanitary absorbent article according to 1.
<9>
The high-density portion of the second sheet has an area in a plan view of 0.3 mm ² or more and 2.0 mm ² or less, preferably 0.5 mm ² or more and 1.5 mm ² or less <5> to <8> The sanitary absorbent article according to any one of the above.
<10>
The sanitary absorbent article according to any one of <5> to <9>, wherein the high-density portion of the second sheet is arranged in a staggered manner.
<11>
The high density portion of the second sheet has an arrangement number per unit area of 15 / cm ^{2 to} 50 / cm ² , preferably 20 / cm ^{2 to} 40 / cm ² <5> to <10>. The sanitary absorbent article according to any one of 10>.
<12>
The distance between adjacent adjacent high-density portions is 0.5 mm or more and 2.0 mm or less, preferably 0.8 mm or more and 1.5 mm or less, according to any one of <5> to <11> Sanitary absorbent article.
<13>
The sanitary tract according to any one of <1> to <12>, wherein the hemagglutinating agent disposed on the second sheet is present on each of the skin facing surface side and the non-skin facing surface side of the second sheet. Absorbent article.
<14>
The amount of the hemagglutinating agent contained in the second sheet is 0.1 g / m ² or more and 25 g / m ² or less, preferably 0.5 g / m ² or more and 15 g / m ² or less, particularly preferably 1.5 g / m. ² or more 10 g / m ² or less, <1> to sanitary absorbent article according to any one of <13>.
<15>
The sanitary absorbent article according to any one of <1> to <14>, wherein the absorbent body is an absorbent sheet.
<16>
In the cross-sectional view, the absorbent body has a relatively high polymer-rich region in which the mass ratio of the superabsorbent polymer to the total mass of the constituent fibers and the superabsorbent polymer is relatively higher than the polymer-rich region. The sanitary absorbent article according to any one of <1> to <15>, which has an extremely low fiber-rich region.
<17>
The sanitary absorbent article according to <15> or <16>, wherein the polymer-rich region and the fiber-rich region are divided in the thickness direction of the absorbent sheet.
<18>
The sanitary absorbent article according to any one of <15> to <17>, wherein the absorbent body has a multilayer structure formed of an absorbent sheet.
<19>
The absorbent body is composed of a central absorbent sheet formed of an absorbent sheet on the excretory part opposite to the excretory part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet, and the excretory part The sanitary absorbent article according to <18>, wherein middle and high portions are formed in the facing portion.
<20>
The sanitary absorbent article according to any one of <15> to <19>, wherein a slit is provided on the skin-facing surface of the absorbent body.
<21>
The sanitary absorbent article according to <20>, wherein the slit has a width of 0.1 mm to 1 mm, preferably 0.2 mm to 0.8 mm.
<22>
The sanitary absorbent article according to <20> or <21>, wherein the length in the longitudinal direction when the slit is viewed in plan is 10 mm or more and 35 mm or less, preferably 15 mm or more and 25 mm or less.
<23>
The physiological condition according to any one of <1> to <14>, wherein the absorbent body is formed of an absorbent core and a core wrap sheet that wraps the absorbent core, and the skin-facing surface of the absorbent body has an uneven structure. Absorbent articles.
<24>
The sanitary absorbent article according to <23>, wherein the core wrap sheet has wrinkles extending in a longitudinal direction corresponding to a wearer longitudinal direction.
<25>
The sanitary absorbent article according to <24>, wherein the crepe rate of the core wrap sheet is 3% to 25%, preferably 5% to 20%.
<26>
The basis weight of the skin-side adhesive is 1 g / m ² or more and 10 g / m ² or less, preferably 1.5 g / m ² or more and 5 g / m ² or less. Any one of <1> to <25> The sanitary absorbent article as described.
<27>
The sanitary absorbent article according to <26>, wherein the skin-side adhesive is provided in a spiral shape between the top sheet and the second sheet.
<28>
The basis weight of the non-skin side adhesive is 1 g / m ² or more and 10 g / m ² or less, preferably 1.5 g / m ² or more and 5 g / m ² or less. Any one of <2> to <27> The sanitary absorbent article according to 1.
<29>
The sanitary absorbent article according to <28>, wherein the non-skin-side adhesive is provided in a spiral shape that is long in the vertical direction or a Ω shape that is long in the vertical direction X.
<30>
The sanitary absorbent article according to any one of <1> to <29>, wherein the hemagglutinating agent is a cationic polymer.
<31>
<30> The sanitary absorbent article according to <30>, wherein the cationic polymer has a molecular weight of 2,000 to 10,000,000, preferably 2,000 to 5,000,000.

Hereinafter, the sanitary absorbent article of the present invention will be described in more detail with reference to examples. However, the scope of the present invention is not limited by the examples.

<Example 1>
A sanitary napkin having the same basic structure as the sanitary napkin 1 shown in FIGS. 1 to 3 having the second sheet and the absorber shown in FIG. 4 was prepared, and this was used as a sample of Example 1. As the surface sheet, one produced by the method described later was used. As an absorptive sheet which comprises an absorber, it created according to Example 2 of patent 2963647. However, High Bulk Additive HBA manufactured by Weyerhauser Paper was used as the crosslinked pulp, and Aqualic CA manufactured by Nippon Shokubai Co., Ltd. was used as the highly absorbent polymer. As the second sheet, a sheet prepared by the method described later was used, and the entire sheet was coated so as to contain a hemagglutinating agent of 1.5 g / m ² . As the cationic polymer contained in the hemagglutinating agent, trade name Marcoat 106 manufactured by Nippon Lubrizol Co., Ltd. (polydiallyldimethylammonium chloride which is a quaternary ammonium salt homopolymer, weight average molecular weight 15,000, IOB value 2) 10 and a streaming potential of 6700 μeq / L) were used. In addition, the compression part was not formed in the second sheet. Moreover, the skin side adhesive which fixes a surface sheet and a 2nd sheet | seat was applied spirally using the spray gun, and the basic weight of coating was 4 g / m < ² >. Similarly, the non-skin-side adhesive that fixes the second sheet 5 and the absorber was applied in a spiral shape using a spray gun, and the basis weight of the application was 3 g / m ² . Further, the slit disposed in the absorber had a width W44 of 0.5 mm, a vertical length L44 of 20 mm, and a distance D44 between the vertical slits of 12 mm. By arranging the slits in this way, the skin-facing surface of the absorber was made to have an uneven structure.
(Preparation of surface sheet)
A core-sheath type composite fiber (core is polypropylene and sheath is polyethylene) having a fiber diameter of 4.0 dtex elongation ratio of 6% and a non-extendable core-sheath type composite fiber (core is polyethylene terephthalate, sheath is 3.3 dtex) Polyethylene) is passed through a card machine at a ratio of 50 wt% to form a web, and the web is introduced into a heat embossing device, and linear depressions 20 (first linear depressions 20a and second depressions are formed on the web). A plurality of linear depressions 20b) were formed. Next, the web was introduced into a hot air spraying apparatus, and hot air treatment was performed by air-through processing to obtain a surface sheet having a partitioned region 22 partitioned by a linear depression 20. The formation pattern of the linear depressions 20 of the obtained topsheet is the pattern shown in FIG. 5, and the width W1 of each of the first and second linear depressions 20a and 21b is 0.5 mm, the first line The interval between the two dents 20a and the interval W2 between the second linear dents 20b are 6 mm, and the angle α between the first linear dent 20a and the second linear dent 20b is 56. °. Incidentally, the basis weight of the resulting surface sheet was 25 g / m ^2.
(Production of second sheet)
A synthetic fiber made of a polyethylene / polyethylene terephthalate composite resin having a fiber diameter of 2.2 dtex is passed through a card machine to form a web. The web is introduced into a hot air blowing device, subjected to hot air treatment by air-through processing, and then roll embossed. A second sheet was obtained. The obtained second sheet had a thickness of 0.3 mm and a basis weight of 25 g / m ² .

<Example 2>
In the sample of Example 1, the hemagglutinating agent was trade name PAS-H-5L (polydiallyldimethylammonium chloride, a quaternary ammonium salt homopolymer, weight average molecular weight 30,000, flow potential 7447 μeq / L, IOB2.1), and the sample of Example 2 was produced in the same manner as in Example 1 except that.

<Comparative example>
In the sample of Example 1, the second sheet was replaced with a second sheet not coated with the hemagglutinating agent, and a sample of a comparative example was produced in the same manner as in Example 1 except that.

[Evaluation]
About the sample (sanitary napkin) of Examples 1 and 2 and the sample of the comparative example (sanitary napkin), the dynamic diffusion area, the liquid return amount, the static absorption time, and the static diffusion area were evaluated by the following methods, respectively. did. The results are shown in Table 2 below.

<Measurement of dynamic diffusion area>
Each sample of Example 1, Example 2, and Comparative Example was evaluated using the movable female waist model described in paragraphs [0082] and [0083] of JP-A-9-187476. After attaching each sample to the movable female waist model and putting on shorts, while walking at a speed of 100 steps / minute, inject 2 g of simulated blood 3 times at 3 minute intervals to a total of 6 g, ( (Pseudo blood injection speed is 1 g for 15 seconds) Remove the napkin from the movable female waist model, write the outline of the red-spread portion on the top sheet, measure the diffusion area of the top sheet, and the simulated blood on the absorber The diffusion area of the adhering absorber was measured. The measurement of each diffusion area was carried out by using a NEWQUE (manufactured by NEXTUS) (ver. 4.20) as an image analysis apparatus (through a CCD camera or a scanner).
The simulated blood was measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) as described in this specification. The blood cell / plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Laboratories Co., Ltd.) was prepared so that the viscosity obtained was 8 mPa · s.

<Measurement of dynamic liquid return amount>
Each sample of Example 1, Example 2 and Comparative Example was spread and placed on a test bench, and an elliptical cylinder made of acrylic having a major axis of 50 mm, a minor axis of 22.5 mm, and a cylinder height of 30 mm was placed on the sample. Place the acrylic injection plate with the part integrally formed so that the injection hole is located at the center of the excretory part facing part on the skin facing surface (surface sheet side) of the sample, and place an appropriate weight plate The load (including the injection plate itself) was adjusted so that the load was 5 g / m ² . 6 g of simulated blood was measured in a 10 cc injection beaker. This simulated blood was injected into the cylinder of the injection plate at once. After leaving the sample in a pressurized state for 2 minutes, the injection plate was removed together with the weight, and 10 sheets of pre-weighed absorbent paper (length 170 mm, width 70 mm, basis weight 35 g / cm ² ) were stacked, The sample was placed on the surface, and the sample was quickly attached to the crotch portion of the shorts and attached to the dynamic walking model and allowed to walk for 1 minute. After walking, the model stopped moving, the absorbent paper was taken out and weighed, and the amount of liquid (g) absorbed by the absorbent paper was calculated. Each sample was measured three times, and the average value was taken as the dynamic liquid return amount of the sample.

<Measurement of static absorption time>
Each sample of Example 1, Example 2 and Comparative Example was spread and placed on an experimental table, and an acrylic injection in which a cylinder having a diameter of 10 mm and an acrylic injection cylinder having a cylinder height of 50 mm were integrally formed on the sample. Place the liquid plate so that the liquid injection hole is located in the center of the excretory part facing part on the skin facing surface (surface sheet side) of the sample, and put the simulated blood obtained by measuring 3 g in a 10 cc liquid injection beaker. It poured into the cylinder of the injection plate at once. After injection, the state was held for 3 minutes. Next, the above-mentioned liquid injection plate was overlaid again on the sample after the test, and after 3 minutes from the first injection, 3 g of adjusted pseudo blood was again injected from the injection port. The injection position of the simulated blood into each sample of Example 1, Example 2, and Comparative Example was the same as the position where the first 3 g was injected. After injection, the state was held for 3 minutes. Subsequently, the above-mentioned injection plate was again superimposed on the sample after the test, and 3 g of simulated blood was added again from the injection port 3 minutes after the second injection. The injection position of the simulated blood into each sample of Example 1, Example 2, and Comparative Example was the same as the position where the second 3 g was injected. From the moment when the pouring was completed, the time (seconds) from when the blood in the cylinder disappeared until the surface sheet of the sample was exposed was measured. Each sample was measured three times, and the average value was taken as the static absorption time of the sample.

<Measurement of static diffusion area>
Immediately after the measurement of the static absorption time was completed, the OHP film was placed on the top sheet, and the outline of the portion that was reddish was written on the top sheet. Using dedicated software (Image-ProPlus: manufactured by Nippon Roper Co., Ltd.) that can measure the area inside the contour, the image written on the OHP film was taken into a personal computer with a scanner and the liquid diffusion area was determined. Each sample was measured three times, and the average value was taken as the static diffusion area of the sample.

According to the results in Table 2, it was found that the sanitary napkins of Examples 1 and 2 had a shorter static absorption time than the sanitary napkins of the comparative examples, and were able to absorb bodily fluids quickly. Moreover, it turned out that the sanitary napkin of Example 1 and 2 also has a small amount of dynamic liquid return compared with the sanitary napkin of a comparative example.
As shown in Table 2, the sanitary napkin of Examples 1 and 2 is a sanitary napkin of the comparative example because the dynamic diffusion area of the absorbent body is large despite the small dynamic diffusion area of the topsheet. Compared to a napkin, body fluid can be sufficiently stocked temporarily, so that it is possible to absorb body fluid quickly and effectively prevent body fluid from returning to the wearer's skin.

According to the sanitary absorbent article of the present invention, bodily fluids can be quickly absorbed, and the return of bodily fluids can be effectively prevented.

Claims (31)

1. Physiological device comprising an absorbent body containing a superabsorbent polymer, a top sheet and a back sheet sandwiching the absorbent body, and a second sheet composed of a non-woven fabric disposed between the top sheet and the absorbent body An absorbent article,
   The second sheet includes a water-soluble hemagglutinating agent, a skin-side adhesive is disposed between the top sheet and the second sheet, and the top sheet and the skin facing surface of the second sheet are partially The sanitary absorbent article is fixed to the surface of the absorbent article, and the position where the hemagglutinating agent is disposed overlaps the position where the skin-side adhesive is disposed, as viewed from above.
2. A non-skin side adhesive is disposed between the second sheet and the absorber, and the non-skin facing surface of the second sheet and the absorber are partially fixed,
   2. The sanitary absorbent article according to claim 1, wherein when the absorbent article is viewed in plan, a position where the hemagglutinating agent is arranged overlaps a position where the non-skin-side adhesive is arranged.
3. The absorbent article according to claim 1 or 2, wherein at least the skin-facing surface of the absorbent body has an uneven structure.
4. The sanitary absorbent article according to any one of claims 1 to 3, wherein the second sheet has a plurality of high-density portions in which the density of constituent fibers separated from each other is increased.
5. The second sheet is divided into the high density part and a low density part other than the high density part,
   The hemagglutinating agent is present in the high-density part and the low-density part, and is present more in the high-density part side than in the low-density part side. Sanitary absorbent article.
6. The sanitary absorbent article according to any one of claims 1 to 5, wherein a width of the second sheet is shorter than a width of the absorber.
7. The sanitary absorbent article according to any one of claims 1 to 6, wherein the second sheet on which the hemagglutinating agent is disposed has a thickness of 0.1 mm or more and 1 mm or less.
8. The high-density portion of the second sheet according to any one of claims 5 to 7, wherein a shape of the second sheet when viewed from the skin-facing surface side is a circle, an ellipse, a square, a rectangle, or a triangle. The sanitary absorbent article as described.
9. The sanitary absorbent article according to any one of claims 5 to 8, wherein the high-density portion of the second sheet has an area in a plan view of 0.3 mm ² or more and 2.0 mm ² or less.
10. The sanitary absorbent article according to any one of claims 5 to 9, wherein the high-density portion of the second sheet is arranged in a staggered manner.
11. The sanitary absorbent article according to any one of claims 5 to 10, wherein the number of arrangement per unit area of the high-density portion of the second sheet is 15 / cm ² or more and 50 / cm ² or less.
12. The sanitary absorbent article according to any one of claims 5 to 11, wherein an interval between the adjacent adjacent high density portions is 0.5 mm or more and 2.0 mm or less.
13. The sanitary absorbability according to any one of claims 1 to 12, wherein the hemagglutinating agent disposed on the second sheet is present on each of the skin facing surface side and the non-skin facing surface side of the second sheet. Goods.
14. The sanitary absorbent article according to any one of claims 1 to 13, wherein an amount of the hemagglutinating agent contained in the second sheet is 0.1 g / m ² or more and 25 g / m ² or less.
15. The sanitary absorbent article according to any one of claims 1 to 14, wherein the absorbent body comprises an absorbent sheet.
16. In the cross-sectional view, the absorbent body has a relatively high polymer-rich region in which the mass ratio of the superabsorbent polymer to the total mass of the constituent fibers and the superabsorbent polymer is relatively higher than the polymer-rich region. The sanitary absorbent article according to any one of claims 1 to 15, which has a low fiber-rich region.
17. The sanitary absorbent article according to claim 16, wherein the polymer-rich region and the fiber-rich region are divided in the thickness direction of the absorbent sheet.
18. The sanitary absorbent article according to any one of claims 15 to 17, wherein the absorbent body has a multilayer structure formed of an absorbent sheet.
19. The absorbent body is composed of a central absorbent sheet formed of an absorbent sheet on the excretory part opposite to the excretory part of the wearer when worn, and a main body absorbent sheet covering the central absorbent sheet, and the excretory part The sanitary absorbent article according to claim 18, wherein middle and high portions are formed in the facing portion.
20. The sanitary absorbent article according to any one of claims 15 to 19, wherein a slit is provided on the skin-facing surface of the absorbent body.
21. The sanitary absorbent article according to claim 20, wherein the slit has a width of 0.1 mm to 1 mm.
22. The sanitary absorbent article according to claim 20 or 21, wherein the length in the longitudinal direction when the slit is viewed in plan is 10 mm or more and 35 mm or less.
23. The sanitary absorption according to any one of claims 1 to 14, wherein the absorbent body is formed of an absorbent core and a core wrap sheet that wraps the absorbent core, and the skin-facing surface of the absorbent body has an uneven structure. Sex goods.
24. 24. The sanitary absorbent article according to claim 23, wherein the core wrap sheet has wrinkles extending in a longitudinal direction corresponding to a wearer longitudinal direction.
25. The sanitary absorbent article according to claim 24, wherein the crepe rate of the core wrap sheet is 3% or more and 25% or less.
26. The sanitary absorbent article according to any one of claims 1 to 25, wherein a basis weight of the skin-side adhesive is 1 g / m ² or more and 10 g / m ² or less.
27. The sanitary absorbent article according to claim 26, wherein the skin side adhesive is provided in a spiral shape between the top sheet and the second sheet.
28. The sanitary absorbent article according to any one of claims 2 to 27, wherein the basis weight of the non-skin side adhesive is 1 g / m ² or more and 10 g / m ² or less.
29. The sanitary absorbent article according to claim 28, wherein the non-skin-side adhesive is provided in a spiral shape that is long in the longitudinal direction or an Ω shape that is long in the longitudinal direction X.
30. The sanitary absorbent article according to any one of claims 1 to 29, wherein the hemagglutinating agent is a cationic polymer.
31. The sanitary absorbent article according to claim 30, wherein the molecular weight of the cationic polymer is 2000 or more and 10 million or less.

Images